AstraZeneca
AZN
168.44
+4.49
+2.74%
AstraZeneca
US · AZN
#68 by market cap
Listed 1970
168.44
+4.49
+2.74%
Live - 5344 symbols - heartbeat 472s ago
· 2026-10-20 10:50
Analyst consensus 15 analysts
Buy
Avg price target 212.28 +26.0%
Price target rangecurrent 168.44
Low155.10
Avg212.28
High261.86
Buy 87%
Hold 7%
Sell 7%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-07 | Bernstein | -- | Buy | 261.86 |
| 2026-10-07 | Berenberg Bank | -- | Buy | 198.38 |
| 2026-10-07 | Jefferies | -- | Buy | 231.44 |
| 2026-10-06 | Citi | -- | Buy | 245.99 |
| 2026-10-05 | BofA Securities | -- | Buy | 218.21 |
| 2026-10-05 | Citi | -- | Buy | -- |
| 2026-10-05 | Barclays | -- | Buy | 211.60 |
| 2026-10-01 | Barclays | -- | Buy | 211.77 |
| 2026-09-29 | Bernstein | -- | Buy | 267.73 |
| 2026-09-29 | BofA Securities | -- | Buy | 218.39 |
| 2026-09-29 | Jefferies | -- | Buy | 231.94 |
| 2026-09-29 | Citi | -- | Buy | 235.59 |
| 2026-09-29 | Goldman Sachs | -- | Buy | 218.56 |
| 2026-09-29 | RBC Capital | -- | Buy | 191.76 |
| 2026-09-29 | J.P. Morgan | -- | Buy | 211.60 |
| 2026-09-21 | RBC Capital | -- | Buy | 192.11 |
| 2026-09-16 | UBS | -- | Buy | 201.02 |
| 2026-09-14 | Bernstein | -- | Buy | 267.63 |
| 2026-09-14 | Berenberg Bank | -- | Buy | 198.81 |
| 2026-09-14 | BofA Securities | -- | Buy | 218.61 |
| 2026-09-14 | Jefferies | -- | Buy | 231.86 |
| 2026-09-14 | RBC Capital | -- | Buy | 193.26 |
| 2026-09-14 | J.P. Morgan | -- | Buy | 211.99 |
| 2026-09-10 | Berenberg Bank | -- | Buy | 215.79 |
| 2026-09-10 | HSBC | -- | Hold | 184.09 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: HSBC moved from Buy to Hold on 2026-07-13.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-07-13 | HSBC | Buy → Hold | 186.44 |
| 2026-04-29 | DZ BANK AG | Hold → Buy | 217.99 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-27 | -- | ±5.62% | +0.22% (in line) |
| 2026/Q1 | 2026-04-29 | -- | ±5.04% | -0.79% (in line) |
| 2025/Q4 | 2026-02-10 | -- | ±5.42% | +2.87% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±3.83% | +3.23% (in line) |
| 2025/Q2 | 2025-07-29 | -- | ±3.93% | +2.99% (in line) |
| 2025/Q1 | 2025-04-29 | -- | ±5.07% | +2.55% (in line) |
| 2024/Q4 | 2025-02-06 | -- | ±5.19% | +2.01% (in line) |
| 2024/Q3 | 2024-11-12 | -- | ±5.55% | +0.62% (in line) |
| 2024/Q1 | 2024-04-25 | -- | ±4.52% | +5.38% (beat) |
| 2023/Q3 | 2023-11-09 | -- | ±3.40% | +0.88% (in line) |
| 2023/Q2 | 2023-07-28 | -- | ±3.60% | +4.71% (beat) |
| 2023/Q1 | 2023-04-27 | -- | ±3.50% | +0.18% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-20 10:50:14 · For reference only, not investment advice and not tailored to your situation.
AstraZeneca discussion 0 comments